Heron Therapeutics Q1 EPS Loss of $0.04 Misses Estimates, Revenue Slips
Heron Therapeutics posted a Q1 net loss of $0.04 per share, missing the consensus loss estimate of $0.03 and reversing from a $0.01 profit in Q1 2025. Q1 revenue also lagged analyst forecasts, highlighting ongoing sales challenges for its oncology supportive-care products.
1. Q1 Earnings Miss
Heron Therapeutics reported a first-quarter net loss of $0.04 per share, wider than the $0.03 loss analysts expected and a reversal from the $0.01 per share profit posted in Q1 2025.
2. Revenue Underperformance
First-quarter revenue fell below consensus projections, indicating slower uptake of its oncology supportive-care therapies and underscoring persistent headwinds in product sales growth.
Related News
JEPQ
JPMorgan ETF Offers 9.5% Yield with Hidden ELN Counterparty Risk
JEPQ•
PII
Polaris Launches $9,999 RANGER 500 and Installs 8,000 m² Solar Array
PII•
NVDA
Nvidia Projects $20 Billion in CPU Sales Within $200 Billion Market
NVDA•
GS
Goldman Sachs to Lead $1.75 Trillion SpaceX IPO With $1.45B Bitcoin Disclosure
GS•
ODV
Osisko Development Raises US$275M via 4.125% Convertible Notes with 25% Premium
ODV•
Sources
FZ